J&J beats Q4 estimates with strong sales and FDA approval for AZN/Daiichi drug

From Zacks Investment Research: 2025-01-24 16:12:28

J&J beat Q4 estimates with earnings of $2.04 per share and $22.5 billion in sales. FDA approved AstraZeneca/Daiichi’s Dato-DXd for breast cancer. SNY, ABBV, RHHBY, and NVS will announce Q4 results next week. J&J’s Q4 sales rose 5.3% to $22.52 billion, with Innovative Medicines outperforming. J&J expects 2025 sales of $89.2-$90.0 billion and adjusted EPS of $10.50-$10.70. FDA approved Spravato as a monotherapy for treatment-resistant depression. FDA approved AZN/Daiichi’s Dato-DXd for HR+ HER2- breast cancer. EU approved SNY’s Sarclisa for first-line multiple myeloma. AbbVie announced a deal with Neomorph for molecular glue degraders.



Read more at Zacks Investment Research: Pharma Stock Roundup: JNJ’s Q4 Earnings, FDA Nod to AZN, Daiichi Drug – January 24, 2025